WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 9, 2024, at 7:00 a.m. PT/10:00 a.m. ET during the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California. Members of the Syndax management team will be joined by multiple key opinion ...

– New monotherapy and combination data in acute leukemia further highlight revumenib's compelling clinical profile –  – 64% ORR (62/97) in expanded dataset of patients with R/R KMT2Ar acute leukemia in Ph 2 AUGMENT-101 pivotal cohort ––  88% ORR (23/26) in SAVE trial testing revumenib, venetoclax and decitabine/cedazuridine combination in R/R AML –WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that multiple abstracts evaluating revumenib, an oral small mole ...

– Rapid responses and symptom improvement observed in inflammatory and fibrotic manifestations of chronic GVHD in heavily pretreated patients –WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq:SNDX), today announced that multiple abstracts evaluating Niktimvo™ (axatilimab-csfr), an anti-CSF-1R antibody for the treatment of chronic graft-versus-host disease (GVHD), have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting being held in San D ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Ashland (ASH) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 6. O ...

CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company’s abstracts accepted for presentation at the upcoming 66th Annual Meeting of the American Society for Hematology (ASH). A live webcast of the prese ...

Ashland Inc. (ASH) has accelerated the application of its new super wetting technology platform, which was unveiled last September. The company has commercialized the easy-wet 300 n super wetting agent for corn, soy and wheat, as well as watermelon, flowers and other produce such as bananas, lettuce and tomatoes.  Successful field trials and client pilots over the last year have validated Ashland's strategy and demonstrated its commitment to rapidly scaling high-performance, creative and sustainable technol ...

Ashland Inc. (ASH) has announced that it completed the sale of its nutraceuticals business to an affiliate of Turnspire Capital Partners LLC on Aug. 30, 2024. The transaction includes custom formulation and contract manufacturing capabilities for the nutrition market from production facilities in New Jersey and Utah, the United States, as well as Tamaulipas, Mexico. The financial terms of the deal were not disclosed.The nutraceuticals business has a wide range of proprietary ingredients, formulations and ma ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are t ...

Financial Data and Key Metrics Changes - Ashland's Q3 sales were approximately $544 million, roughly in line with the prior year, with a 3% reduction due to portfolio improvement initiatives [9][15] - Adjusted EBITDA for the quarter increased to $139 million, representing a 5% increase from the prior year, with an adjusted EBITDA margin of 25.6%, up from 24.4% [12][16] - Adjusted EPS for the quarter was $1.49 per share, up 21% from the prior-year quarter [16] Business Line Data and Key Metrics Changes - Personal Care sales increased by 20% to $175 million, with adjusted EBITDA rising 46% to $51 million, marking one of the most profitable quarters for this segment [18] - Specialty Additives sales declined by 1% to $150 million, but adjusted EBITDA increased by 31% to $38 million, with a recovery in adjusted EBITDA margin to 25.3% [20] - Life Sciences sales decreased by 11% to $195 million, with adjusted EBITDA down 18% to $59 million, primarily due to lower VP&D volumes [17] Market Data and Key Metrics Changes - Sales in North America, Europe, and Asia were stable to improving, while Latin America and the Middle East Africa showed weakness [15] - The regional recovery was mixed, with lower demand and increased competition in Asia, particularly affecting Specialty Additives [11] Company Strategy and Development Direction - Ashland is focused on portfolio optimization, including the sale of its nutraceutical business and reducing exposure to lower-margin segments [25][26] - The company aims to strengthen its competitive position in VP&D and HEC, with ongoing efforts to drive share gains [32][34] - Ashland continues to invest in technology platforms and new product launches to enhance growth opportunities [37][39] Management's Comments on Operating Environment and Future Outlook - Management noted that June sales were weaker than expected, a trend that continued into July, particularly affecting Specialty Additives [9][28] - The company expects Q4 sales in the range of $530 million to $540 million, with adjusted EBITDA between $130 million and $140 million, reflecting challenges in VP&D and softer market demand [30][40] - Management emphasized the importance of managing pricing and volume dynamics in a competitive environment, particularly in the VP&D segment [44][70] Other Important Information - Ashland repurchased $130 million of shares during the quarter and increased its dividend, reflecting confidence in long-term growth [12][24] - The company has a strong financial position with cash on hand of $399 million and total available liquidity of roughly $1 billion [22] Q&A Session Summary Question: Can you help us think about the 2025 bridge regarding fixed cost absorption and market growth? - Management indicated that the key issue is the VP&D and pharma share dynamics, with expectations for 2024 remaining largely unchanged except for the VP&D market share outlook [44][48] Question: What markets are seeing a downtick in demand? - Management noted that the biggest impact is in Specialty Additives, particularly coatings, with slower-than-expected growth in North America and Europe [55][56] Question: Can you size the VP&D pharma issue? - Management estimated that the VP&D issue resulted in a delta of around $14 million in Q3 compared to the prior year [64] Question: What is driving the pricing weakness in Personal Care and Specialty Additives? - Management explained that pricing dynamics are influenced by raw material deflation and competitive pressures, particularly in Asia [58][60] Question: How is the company managing the VP&D share loss? - Management stated that they are balancing pricing and volume gains, with ongoing negotiations with customers expected to impact future volumes [70][72]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-211719 (a Delaware corporation) I.R.S. No. 81-2587835 8145 Blazer Drive Wilmington, Delaware 19808 Telephone Number (302) 995-300 ...